13 completed, 7 terminated, 5 recruiting, 3 withdrawn. 17 Phase 2, 11 Phase 1, 2 Not applicable, 1 Phase 3.
Follow Acrocephalosyndactylia: new trials by email Literature Review of Acrocephalosyndactylia trials Research Report on Acrocephalosyndactylia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Futibatinib, Zimberelimab, Durvalumab - Biliary Tract Cancer | Phase 3 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 784 | 2026-06-24 | 2026-07-17 |
| ASO Treatment for Syndromic Craniosynostoses Design of patient specific ASO - Craniosynostoses, Crouzon Syndrome | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 12 | 2026-04-20 | 2026-09-08 | |
| A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 humanized monoclonal anti-FGFR1 antibody OM-RCA-01 - Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Kidney Cancer Research Bureau | 58 | 2025-12-02 | 2026-01-21 |
| Driving Pressure-guided Tidal Volume Ventilation in the Acute Respiratory Distress Syndrome Tidal volume customization in the acute respiratory distress syndrome - Acute Respiratory Distress Syndrome ARDS | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 750 | 2024-09-01 | 2024-03-26 |
| Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles - Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 | Active not recruiting | Tyra Biosciences, Inc | 40 | 2023-11-22 | 2026-10-14 |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Active not recruiting | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-08-28 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Pemigatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Incyte Corporation | 8 | 2022-04-29 | 2025-08-05 |
| Phase I BLASST-3 Trial Infigratinib - Bladder Transitional Cell Carcinoma, Bladder Cancer | Phase 1 | Withdrawn | Guru P. Sonpavde | 2021-12-23 | 2022-08-10 | |
| NCCH2006/MK010 Trial (FORTUNE Trial) E7090 - Advanced or Recurrent Solid Tumors, FGFR Gene Alterations | Phase 2 | Recruiting | National Cancer Center, Japan | 75 | 2021-06-15 | 2025-10-03 |
| A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer E7090, Fulvestrant, Exemestane - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 51 | 2020-10-09 | 2026-07-17 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Pemigatinib, Pembrolizumab, Gemcitabine - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Terminated | Incyte Corporation | 7 | 2020-05-14 | 2025-11-04 |
| Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations Infigratinib - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | LianBio LLC | 80 | 2020-05-13 | 2022-06-27 |
| A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion E7090 - Cholangiocarcinoma | Phase 2 | Completed | Eisai Co., Ltd. | 63 | 2020-01-22 | 2026-03-02 |
| Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety Rogaratinib (BAY1163877), Combination drug - Cancer | Phase 2 | Completed | Bayer | 1 | 2019-10-30 | 2022-04-01 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Pemigatinib - Solid Tumor Malignancy | Phase 2 | Terminated | Incyte Corporation | 111 | 2019-10-17 | 2025-11-04 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 95 | 2019-08-02 | 2023-10-13 |
| A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations Archival Tumor Tissue Sample - Urothelial Cancer, Receptors, Fibroblast Growth Factor | Completed | Janssen Research & Development, LLC | 3679 | 2019-08-01 | 2023-02-24 | |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Rogaratinib - Squamous-cell Non-small Cell Lung Cancer | Phase 2 | Terminated | Swiss Cancer Institute | 15 | 2019-07-25 | 2022-11-09 |
| GROWing Up With Rare GENEtic Syndromes Retrospective file studies - Prader-Willi Syndrome, PWS-like Syndrome | Recruiting | dr. Laura C. G. de Graaff-Herder | 600 | 2018-10-01 | 2023-09-06 |
Showing 20 of 33. Sign in to see all of them.
Neoplasms (6) · Cholangiocarcinoma (5) · Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Transitional Cell (4) · Neoplasm Metastasis (3) · Urinary Bladder Neoplasms (3) · Cleft Lip (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · 22q11 Deletion Syndrome (1) · Adrenal Hyperplasia, Congenital (1)
Bone Diseases (33) · Bone Diseases, Developmental (33) · Congenital Abnormalities (33) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (33) · Craniofacial Abnormalities (33) · Dysostoses (33) · Limb Deformities, Congenital (33) · Musculoskeletal Abnormalities (33) · Musculoskeletal Diseases (33) · Syndactyly (33) · Synostosis (33) · Craniosynostoses (32) · Neoplasms (19) · Neoplasms by Site (16) · Neoplasms by Histologic Type (12)
pemigatinib (6) · infigratinib (3) · Gemcitabine (2) · Rogaratinib (2) · derazantinib (2) · erdafitinib (2) · pembrolizumab (2) · Alpelisib (1) · Carboplatin (1) · Cisplatin (1) · Drug Combinations (1) · E-3810 (1) · Fulvestrant (1) · INCB 54828-101 (1) · Irinotecan (1)
Incyte Corporation (7) · Janssen Research & Development, LLC (3) · Basilea Pharmaceutica (2) · Eisai Co., Ltd. (2) · Teresa Helsten, MD (2) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Guru P. Sonpavde (1) · Janssen Pharmaceutical K.K. (1) · Kidney Cancer Research Bureau (1) · LianBio LLC (1) · M.D. Anderson Cancer Center (1) · National Cancer Center, Japan (1) · National Human Genome Research Institute (NHGRI) (1)
United States (16) · France (11) · Japan (11) · Italy (10) · Spain (10) · Germany (9) · Belgium (7) · South Korea (7) · United Kingdom (7) · Switzerland (5) · Australia (4) · Israel (4) · Canada (3) · China (3) · Netherlands (3)
Ekaterine Asatiani, MD (2) · Teresa Helsten, MD (2) · Alfredo Addeo, MD (1) · Barbara B Biesecker (1) · Doug Warner (1) · Guru Sonpavde, MD (1) · Luis F. Vinas, MD (1) · Luis Feliz Vinas, MD (1) · Luisa Veronese, MD (1) · Michael Overman, MD (1)
PMID 16428493, PMID 18297062, PMID 18635960, PMID 20818389, PMID 26324363, PMID 31088831, PMID 31280362, PMID 32203698, PMID 35544727, PMID 35945547, PMID 36206041, PMID 36787089, PMID 37956738, PMID 38039831, PMID 38627238, PMID 38710951, PMID 39138436, PMID 42337043
2019 (3), 2016 (2), 2017 (1), 2018 (1)